Zealand Pharma A/S (OMXCOP:ZEAL) disclosed week‑26 buybacks under its May–Oct 2026 program, leaving 2,319,482 treasury shares (≈3.24%) of 71,578,758 outstanding, while The Capital Group reported holding 4.79% of ZEAL voting rights in discretionary client accounts as of June 26, 2026.
Previous Week Recap
- Zealand Pharma Buybacks Reduce Treasury Shares: Zealand Pharma (ZEAL) reported week 26 buybacks under its May–Oct 2026 program. After trades it holds 2,319,482 treasury shares (≈3.24%). Total shares outstanding: 71,578,758.
- Capital Group Holds 4.79% ZEAL Voting Rights: The Capital Group reported holding 4.79% of Zealand Pharma A/S (ZEAL) voting rights as of June 26, 2026; holdings are in discretionary client accounts, not owned by the firm.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.